Janssen Presents Results of Tremfya (guselkumab) in P-II (GALAXI 1) Clinical Trial for the Treatment of Active Crohn's Disease at ECCO 2022
Shots:
- The P-II (GALAXI 1) trial evaluates Tremfya vs Stelara in patients with active CD with inadequate response/intolerance to conventional therapies & biologics
- The results showed that patients treated with 200mg IV/100mg SC achieved clinical remission/corticosteroid-free clinical remission/PROs (63.9%/59%/57.4%), (73%/71.4%/69.8%) with 600mg IV & 200mg SC, 57.4%/55.7%/50.8% with 1200 mg IV/200 mg SC over 58.7%/58.7%/ 46%, respectively
- Additionally, all dose groups @ 48wk. had comparable safety data, consistent with the known safety profile for Tremfya. In dose group of 200mg IV/100mg SC, 600mg IV/200mg SC, 1200mg IV/200mg SC & Stelara, AEs were reported in 71.2%, 80.8%, 69.9% & 84.5%, respectively
Ref: PR Newswire | Image: Medical Dialogues
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].
